Impact Biomedical (IBO) Cash from Financing Activities (2022 - 2026)

Impact Biomedical's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $482000.0 for Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $482000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (changed N/A YoY) and the FY2025 annual result came in at -$109000.0, down 102.25% from the prior year.
• Cash from Financing Activities was $482000.0 for Q1 2026 at Impact Biomedical, up from $317000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $3.7 million in Q3 2024 and bottomed at $232000.0 in Q4 2023.
• A 4-year average of $864454.5 and a median of $539000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 56.96% — and 2024, when it jumped 321.38%.
• Impact Biomedical's Cash from Financing Activities stood at $539000.0 in 2022, then plunged by 56.96% to $232000.0 in 2023, then jumped by 36.64% to $317000.0 in 2024, then jumped by 52.05% to $482000.0 in 2026.
• Business Quant data shows IBO's Cash from Financing Activities at $482000.0 in Q1 2026, $317000.0 in Q4 2024, and $3.7 million in Q3 2024.